← 글 목록← All articles

How does patent term extension work in Korea?

Brief summary

  • Korea extends the term of the patent by the period during which the patented invention could not be worked because of the approval or registration of a drug or a pesticide (허가등, “regulatory approval” below). The extension is up to 5 years and is available only once (Patent Act, Art. 89(1)).
  • The application for registration of an extension of a patent (연장등록출원, “extension application” below) must be filed within 3 months from the date on which regulatory approval is obtained. It cannot be filed from 6 months before the expiration of the term (Patent Act, Art. 90(2)).
  • Two more limits apply where regulatory approval is obtained on or after 22 July 2025. The term cannot be extended beyond 14 years from the date of regulatory approval, and only one patent right can be extended for one regulatory approval.

This article is based on the Patent Act (특허법) in force from 11 November 2025. Last verified on 9 October 2026.

Last verified

Requirements at a glance

As of October 2026. “On or after 22 July 2025” means an extension application for a case in which regulatory approval is obtained on or after that date.

Item Content Basis
Eligible inventions Inventions of a drug that has a new substance as its active ingredient and is the first to receive permission by item, of a narcotic or psychotropic drug, and of a pesticide or technical ingredient that is the first to be registered Enforcement Decree of the Patent Act, Art. 7(1)
Period of extension The period during which the invention could not be worked because of regulatory approval. Up to 5 years Patent Act, Art. 89(1)
Number of extensions Once Patent Act, Art. 89(1)
Cap after approval 14 years from the date of regulatory approval (on or after 22 July 2025) Patent Act, Art. 89(1), proviso
Number of patent rights One patent right for one regulatory approval (on or after 22 July 2025) Patent Act, Art. 90(7)
Time limit to apply Within 3 months from the date of regulatory approval. Not possible from 6 months before the expiration of the term Patent Act, Art. 90(2)
Applicant The patentee. If the patent right is jointly owned, all co-owners Patent Act, Art. 90(3) and Art. 91, subparagraph 4
Person who obtained the regulatory approval The patentee, an exclusive licensee or a registered non-exclusive licensee Patent Act, Art. 91, subparagraph 2
Application fee KRW 300,000 per application Regulation on the Collection of Patent Fees, etc., Art. 2(1), subparagraph 2
Effect of the extended patent right Extends only to acts of working the patented invention for the product that is the subject of the regulatory approval Patent Act, Art. 95

Only new-substance drugs and pesticides are eligible

Two kinds of invention are eligible. They are set out in Article 7(1) of the Enforcement Decree of the Patent Act (특허법 시행령). [3]

The first is the invention of a drug that has received permission by item (approval) under the Pharmaceutical Affairs Act (약사법). Narcotics and psychotropic drugs that have received permission by item under the Narcotics Control Act (마약류 관리에 관한 법률) are in the same subparagraph. [3] The second is the invention of a pesticide or technical ingredient (원제) registered under the Pesticide Control Act (농약관리법). [3]

In both cases, the product must have a new substance as its active ingredient and must be the first to be approved or registered. The Enforcement Decree defines a new substance as a substance in which the chemical structure of the active moiety that produces the medicinal effect is new. [3]

The Patent Examination Guidelines (특허·실용신안 심사기준, “Examination Guidelines” below) cite Supreme Court Decision 2021Hu11070 and explain the meaning of the active moiety narrowly. A substance is not a new substance merely because a part that has no activity by itself is bonded to the active moiety of a previously approved drug. [5]

A Public Notice (Notification) of the Ministry of Intellectual Property (지식재산처, MOIP) provides that, where there are several approvals or registrations for a new substance, only the first one is recognized (Public Notice, Art. 3(4)). [4] The Examination Guidelines give the example of an approval of a product and an approval of a changed dosage form for the same active ingredient. In that case, an extension can be based only on the first approval. [5]

The Examination Guidelines state that an approval or registration under any other statute is not a basis for an extension application. [5] The Examination Guidelines treat the invention of an advanced biological product in the same way as a drug. This means a product that has received permission by item under the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products (첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률). The limits to a new substance and to the first approval are the same. [5]

The Examination Guidelines state that patent rights for an intermediate, for a catalyst used to manufacture the final product, and for manufacturing apparatus are not eligible. [5]

An extension application can be filed only while the patent right is in force. [5] The Public Notice provides that the patent must be valid when the extension application is filed (Public Notice, Art. 2(3)). [4] According to the Examination Guidelines, an extension application can be filed even while a trial for invalidation against the patent right is pending. [5]

The extension equals the period in which the invention could not be worked, up to 5 years

The term of the patent can be extended only once, by the period during which the invention could not be worked, up to 5 years (Patent Act, Art. 89(1)). [1] A period that passed for a cause attributable to the person who obtained the regulatory approval is not included in that period (Art. 89(2)). [1]

Only the period after the date of registration of the grant of a patent (registration of establishment of a patent right; “registration date” below) is counted (Public Notice, Art. 4(1)). [4] A period of clinical trials carried out before the registration is not included.

For drugs other than veterinary drugs, two periods are added together. One is the period of clinical trials carried out with the approval of the Minister of Food and Drug Safety. The other is the period in which the Ministry of Food and Drug Safety reviewed the documents of the application for approval (Public Notice, Art. 4(1), subparagraph 1). [4]

For veterinary drugs, the period of clinical trials approved by the Commissioner of the Animal and Plant Quarantine Agency and the review period at that agency are added together (Art. 4(1), subparagraph 2). [4] For pesticides and technical ingredients, the testing period at a testing and research institution and the period in which the Rural Development Administration reviewed the documents of the application for registration are added together (Art. 4(1), subparagraph 3). [4]

The Examination Guidelines take the clinical trial period as running from the date on which the first subject is selected to the date on which the observation period of the last subject ends. They take the review period as running from the date on which the application for permission by item is received to the date on which the applicant comes to know that the permission by item was granted. [5] A supplementation period that arose for a cause attributable to the person who obtained the regulatory approval is deducted from the review period. [5]

If the date of regulatory approval is earlier than the registration date of the patent right, there is no period during which the invention could not be worked. The Examination Guidelines treat this case as a ground for rejection under Article 91, subparagraph 3 of the Patent Act. [5]

A 14-year cap applies where approval is obtained on or after 22 July 2025

The term of the patent cannot be extended beyond 14 years from the date of regulatory approval (Patent Act, Art. 89(1), proviso). [1] This cap applies to cases in which regulatory approval is obtained on or after 22 July 2025. [1]

The proviso was newly inserted by Act No. 20700. Act No. 20700 was promulgated on 21 January 2025 and took effect on 22 July 2025. [1] Article 2 of the Addenda to that Act provides that the amended provisions apply from extension applications for a patented invention for which regulatory approval is obtained on or after the date on which the Act takes effect. [1]

Therefore, the 14-year cap does not apply to cases in which regulatory approval was obtained on or before 21 July 2025. Article 89(1) of the Patent Act in force from 21 August 2024 had only the 5-year limit and the limit to one extension. [2] The Addenda to the Public Notice also provide that an invention for which regulatory approval was obtained before the effective date is governed by the previous provisions. [4]

The Examination Guidelines state that the 14 years are counted from the date of regulatory approval and include the extended period (Part 7, Chapter 1, 4.2). [5] In the example in the Examination Guidelines, the period from the date of permission by item to the expiration date after a 5-year extension is 16 years. In this case, only 3 years are extended, which is 5 years minus 2 years. [5]

The Public Notice provides that, if the period of extension applied for goes beyond 14 years from the date of regulatory approval, the applicant states the number of days up to the 14 years (Public Notice, Art. 6(1), subparagraph 6). [4]

Some patents already have a registered patent term extension for delay in registration (extension of the term of a patent right following delayed registration; 등록지연에 따른 존속기간 연장). In this case, the term that is the subject of the extension runs to the date as so extended (Patent Act, Art. 89(1), parenthetical). [1] The Examination Guidelines take that extended date as the starting point of the patent term extension for approval, etc. (extension of patent terms by permission; 허가등에 따른 존속기간 연장). [5]

In some cases, the period including the patent term extension for delay in registration goes beyond 14 years from the date of regulatory approval. In such a case, the patent term extension for approval, etc. is not available (Public Notice, Art. 4(3)). [4] This parenthetical in Article 89(1) was also inserted by Act No. 20700. [1][2]

Only one patent right can be extended for one regulatory approval

Where there are two or more patent rights for one regulatory approval, an extension application can be filed for only one of them (Patent Act, Art. 90(7)). [1] This provision applies to cases in which regulatory approval is obtained on or after 22 July 2025. [1]

If extension applications are filed for two or more patent rights for one regulatory approval, the term of none of those patent rights can be extended (Art. 90(7)). [1] The Examination Guidelines give the example of a substance patent, a manufacturing process patent and a use patent that exist separately. If extension applications are filed for all three, none of them is extended. [5]

However, an extension application that has been abandoned, invalidated or withdrawn is deemed never to have been filed for the purpose of this provision. The same applies to an extension application for which a decision of rejection (decision to reject a patent application) or a trial decision to the effect that it is rejected has become final (Patent Act, Art. 90(8)). [1]

Article 90(7) and (8) were also newly inserted by Act No. 20700, and their scope of application is the same as that of the 14-year cap. [1] Article 90 of the Patent Act in force from 21 August 2024 had no paragraph (7). [2]

Conversely, one patent right can be extended only once (Patent Act, Art. 89(1)). [1] The Examination Guidelines explain that, where there are several approvals for several active ingredients covered by one patent, one of them must be chosen. [5]

The application must be filed within 3 months from the date of regulatory approval

The extension application must be filed within 3 months from the date on which regulatory approval is obtained (Patent Act, Art. 90(2), main clause). [1] It cannot be filed from 6 months before the expiration of the term under Article 88 of the Patent Act (Art. 90(2), proviso). [1]

The period is counted under Article 14 of the Patent Act. The first day is not counted, and the period ends on the day before the day in the last month that corresponds to the starting day. [1] If regulatory approval is obtained on 10 March 2026, the 3 months end on 10 June 2026.

The Patent Act has no provision that extends or restores this 3-month period. The only statutory period that Article 15(1) of the Patent Act allows to be extended is the period for filing a petition for trial under Article 132-17. [1] Subsequent completion of a procedure under Article 17 of the Patent Act also applies only to the periods for filing a petition for trial and for retrial. [1]

According to the Examination Guidelines, an extension application filed outside this period is returned after the applicant is given an opportunity to explain. The same applies to an extension application filed before regulatory approval is obtained. [5]

The applicant must be the patentee (Patent Act, Art. 91, subparagraph 4). [1] If the patent right is jointly owned, all co-owners (joint owners) must file the application jointly (Patent Act, Art. 90(3)). [1]

The patentee does not have to be the one who obtains the regulatory approval. However, the application is rejected if the person who obtained the regulatory approval is not the patentee, an exclusive licensee or a registered non-exclusive licensee (Patent Act, Art. 91, subparagraph 2). [1]

The Examination Guidelines treat as this ground for rejection the case in which the approval was obtained by a non-exclusive licensee whose license was not registered when the extension application was filed. The ground for rejection is resolved if the non-exclusive license is registered and evidence is submitted before the certified copy of the decision on whether to register the extension is served. [5]

The extension application states the patent number of the patent right to be extended and the claims to be extended. It also states the period of extension applied for, the details of the regulatory approval and the ground for extension (Patent Act, Art. 90(1)). [1] The form is Form 30 of the Enforcement Rules of the Patent Act (특허법 시행규칙) (Enforcement Rules, Art. 52). [7] The period of extension applied for is stated in days (Public Notice, Art. 6(1), subparagraph 6). [4]

Article 53 of the Enforcement Rules lists, as the ground for extension, the materials in three subparagraphs. [7] Subparagraph 1 is the need to obtain the approval or registration, with evidence. Subparagraph 2 is the period during which the patented invention could not be worked for that reason, with evidence. Subparagraph 3 is evidence that the person who obtained the approval is the patentee, an exclusive licensee or a registered non-exclusive licensee. [7]

The application fee is KRW 300,000 per application (Regulation on the Collection of Patent Fees, etc. (특허료 등의 징수규칙), Art. 2(1), subparagraph 2). [6]

Once the application is filed, the term is deemed extended

When an extension application is filed, the term is deemed to be extended. This does not apply if a decision rejecting registration of the extension becomes final (Patent Act, Art. 90(4)). [1] The Examination Guidelines also treat the term as never having been extended where the extension application is withdrawn, invalidated or returned. [5]

The examiner must issue a decision rejecting registration of the extension if any of the grounds in the subparagraphs of Article 91 of the Patent Act applies. [1] There are six grounds. [1]

  1. Regulatory approval is not found to have been necessary for working the patented invention.
  2. The regulatory approval was not obtained by the patentee, an exclusive licensee or a registered non-exclusive licensee.
  3. The period of extension applied for exceeds the period of extension allowed under Article 89.
  4. The applicant of the extension application is not the patentee.
  5. Not all co-owners filed the application jointly.
  6. Extension applications were filed for two or more patent rights in violation of Article 90(7).

Subparagraph 6 applies only where regulatory approval is obtained on or after 22 July 2025. The previous Article 91 had only subparagraphs 1 to 5. [1][2] The standard in the previous subparagraph 3 was “the period during which the invention could not be worked”. [2]

The applicant can amend some matters in the extension application until the certified copy of the decision on whether to register the extension is served. The patent number of the patent right to be extended cannot be amended (Patent Act, Art. 90(6)). [1] After a notice of grounds for rejection is received, an amendment can be made only within the period for submission of a written argument on that notice (Art. 90(6), proviso). [1]

An appeal against a decision rejecting registration of the extension can be requested within 3 months from the date on which the certified copy of the decision is served (Patent Act, Art. 132-17). [1]

The extended patent right covers only the approved product

The effect of a patent right whose term has been extended extends only to acts of working the patented invention for the product that is the subject of the regulatory approval (Patent Act, Art. 95). [1] If the regulatory approval specifies a particular use for the product, the product used for that use is the standard (Art. 95, parenthetical). [1]

A trial to invalidate the registration of an extension of a patent can be requested. The petitioner is an interested party or an examiner (Patent Act, Art. 134(1)). [1] Where the registration is invalidated because the extended period exceeds the period allowed, only the excess period is deemed not to have been extended (Art. 134(4), subparagraph 1). [1]

The case in which the extension is registered for two or more patent rights for one regulatory approval is also a ground for invalidation (Art. 134(1), subparagraph 6). [1] This subparagraph applies where regulatory approval is obtained on or after 22 July 2025. [1] The Public Notice provides that this trial for invalidation cannot be requested claim by claim (Public Notice, Art. 12(4)). [4]

Example: calculating the 14-year cap

The cases assume that regulatory approval is obtained on or after 22 July 2025. The third row uses the same figures as the example in the Examination Guidelines. [5] “Total” is the period from the approval date to the expiration date after the extension.

Case Term remaining on the approval date Period in which the invention could not be worked After the 5-year limit Total Period of extension
A 6 years 3 years 3 years 9 years 3 years
B 6 years 7 years 5 years 11 years 5 years
C 11 years 5 years 5 years 16 years 3 years

In case C, the total exceeds 14 years by 2 years. Therefore only 3 years are extended, which is 5 years minus 2 years. [5] If regulatory approval had been obtained on or before 21 July 2025, the period of extension in case C would be 5 years. [2]

How Korea differs

The Korean time limit to apply is longer than the US time limit, and the eligible subject matter is narrower than in the United States.

Item Korea United States Japan
Time limit to apply Within 3 months from the date of regulatory approval A 60-day period beginning on the date the approval is received 3 months from the date on which the disposition is obtained
Limit on the extension 5 years 5 years 5 years
Cap after approval 14 years (regulatory approval on or after 22 July 2025) 14 years Not provided for in Art. 67(4) and Art. 67-7 of the Patent Act of Japan (特許法 第67条第4項, 第67条の7)
Basis Patent Act, Arts. 89 and 90 [1] 35 U.S.C. § 156(c)(3), (d)(1), (g)(6)(A) [8] Patent Act of Japan, Art. 67(4) and Art. 67-5(3); Order for Enforcement of the Patent Act (特許法施行令), Art. 3 [9]

The United States includes medical devices, food additives and color additives among the eligible products (35 U.S.C. § 156(f)(1)). [8] Article 7(1) of the Korean Enforcement Decree covers only drugs and pesticides. [3]

The United States also extends only one patent for the same regulatory review period (35 U.S.C. § 156(c)(4)). [8] Korea has introduced a provision in the same direction for cases in which regulatory approval is obtained on or after 22 July 2025. [1]

The 5-year limit in the United States concerns patents issued after the date of enactment of the statute (35 U.S.C. § 156(g)(6)(A)). [8] The US provision was read in the 2023 Edition of the United States Code. The Japanese provisions are the version provided by e-Gov on 9 October 2026.

Japan has an exception for an applicant who could not meet the 3 months for a cause not attributable to the applicant (Order for Enforcement of the Patent Act, Art. 3, proviso). [9] Article 90(2) of the Korean Patent Act has no such proviso. [1]

Japan provides that the application cannot be filed after the term of the patent has expired (Patent Act of Japan, Art. 67-5(3), proviso). [9] In Korea, the application cannot be filed from 6 months before the expiration. [1]

What applicants should do

  • In general, we suggest choosing the candidate patent for extension in advance, at the stage when permission by item is applied for. The 3 months from the date of regulatory approval are a short period for collecting the materials.
  • If several patents relate to one approval, we suggest choosing which patent to extend before the approval. If extension applications are filed for two or more patents, none of them is extended.
  • If a Korean entity or a licensee obtains the approval, we suggest checking first whether the license is registered.
  • We suggest recording from the start the first and last dates of the clinical trials, each request for supplementation and each date on which supplementary materials were submitted. The period of extension applied for must be proved in days.
  • Whether an individual patent can be extended, and for how long, must be confirmed with a Korean agent.

FAQ

Can a medical device patent obtain a patent term extension for approval, etc. in Korea?

The eligible subject matter under Article 7(1) of the Enforcement Decree is drugs, narcotics and psychotropic drugs, and pesticides and technical ingredients. [3] The Examination Guidelines state that an approval or registration under any other statute is not a basis. [5]

What happens if the 3 months from the date of approval are missed?

The extension application cannot be filed. Article 90(2) of the Patent Act requires the application to be filed within 3 months from the date of regulatory approval. [1] According to the Examination Guidelines, an extension application filed after the period is returned after the applicant is given an opportunity to explain. [5] Articles 15 and 17 of the Patent Act do not apply to these 3 months. [1]

Does the 14-year cap apply to a drug approved before 22 July 2025?

No. Article 2 of the Addenda to Act No. 20700 applies the amended provisions from extension applications for cases in which regulatory approval is obtained on or after the date on which the Act takes effect. [1]

Can a patent receive both a patent term extension for delay in registration and a patent term extension for approval, etc.?

Yes, where regulatory approval is obtained on or after 22 July 2025. The parenthetical in Article 89(1) of the Patent Act presupposes a case in which a patent term extension for delay in registration has been registered. [1] However, in some cases the period including the patent term extension for delay in registration goes beyond 14 years from the approval date. In such a case, the patent term extension for approval, etc. is not available (Public Notice, Art. 4(3)). [4]

During the extended period, does the patent right cover the full scope of the claims?

No. The effect extends only to acts of working the patented invention for the product that is the subject of the regulatory approval (Patent Act, Art. 95). [1]

Does the amended Patent Act that takes effect in 2027 change this system?

No. Act No. 21955 takes effect on 16 March 2027. Articles 89 to 93, 95, 132-17 and 134 of that Act are the same as the current provisions. [1][10]

How DEFINE IP Law Firm handles this

For patents in the pharmaceutical and pesticide fields, DEFINE IP Law Firm checks whether a patent term extension for approval, etc. is available at the stage when permission by item is applied for. We use two criteria: the time limit of 3 months from the date of regulatory approval, and the limit of one patent right for one regulatory approval. For questions about patent term extension in Korea, please write to contact@defineip.kr.

Sources

  1. Patent Act (특허법), Act No. 21134, in force from 11 November 2025. Articles 14, 15, 17, 88, 89, 90, 91, 92, 93, 95, 132-17 and 134; Addenda (Act No. 20700, promulgated 21 January 2025, in force from 22 July 2025), Arts. 1 and 2. https://www.law.go.kr/법령/특허법 (verified 9 October 2026)
  2. Patent Act (특허법), Act No. 20322, in force from 21 August 2024 (provisions before the amendment). Articles 89, 90 and 91. Revision history at https://www.law.go.kr/법령/특허법 (verified 9 October 2026)
  3. Enforcement Decree of the Patent Act (특허법 시행령), Presidential Decree No. 35809, in force from 1 October 2025. Article 7. https://www.law.go.kr/법령/특허법시행령 (verified 9 October 2026)
  4. Ministry of Intellectual Property (지식재산처), Regulations on the Operation of the Extension of the Term of Patent Rights Based on Approvals, etc. (허가등에 따른 특허권 존속기간의 연장제도 운용에 관한 규정), MOIP Notification No. 2025-4, in force from 30 October 2025. Articles 2, 3, 4, 6 and 12; Addenda (No. 2025-10, issued 7 July 2025, in force from 22 July 2025), Art. 2. https://www.law.go.kr/행정규칙/허가등에따른특허권존속기간의연장제도운용에관한규정 (verified 9 October 2026)
  5. Ministry of Intellectual Property (지식재산처), Patent Examination Guidelines (특허·실용신안 심사기준), MOIP Established Rule No. 7, issued 12 March 2026, in force from 13 March 2026. Part 7, Chapter 1 “허가등에 따른 특허권의 존속기간의 연장” (Patent Term Extension for Approval, etc.), 3.1, 3.2, 3.3, 3.4, 4.1, 4.2, 5.3, 5.5 and 6.4.2. https://www.law.go.kr/행정규칙/특허·실용신안심사기준 (verified 9 October 2026)
  6. Regulation on the Collection of Patent Fees, etc. (특허료 등의 징수규칙), Prime Ministerial Decree No. 2098, in force from 27 February 2026. Article 2(1), subparagraph 2. https://www.law.go.kr/법령/특허료등의징수규칙 (verified 9 October 2026)
  7. Enforcement Rules of the Patent Act (특허법 시행규칙), Prime Ministerial Decree No. 2115, in force from 14 May 2026. Articles 52 and 53. https://www.law.go.kr/법령/특허법시행규칙 (verified 9 October 2026)
  8. 35 U.S.C. § 156, United States Code 2023 Edition. https://www.govinfo.gov/content/pkg/USCODE-2023-title35/html/USCODE-2023-title35-partII-chap14-sec156.htm (verified 9 October 2026)
  9. Patent Act of Japan (特許法, 昭和三十四年法律第百二十一号), 第67条第4項, 第67条の5 and 第67条の7, and Order for Enforcement of the Patent Act (特許法施行令, 昭和三十五年政令第十六号), 第3条, e-Gov 法令検索. https://laws.e-gov.go.jp/law/334AC0000000121 (verified 9 October 2026)
  10. Patent Act (특허법), Act No. 21955, promulgated 15 September 2026, scheduled to take effect on 16 March 2027. Articles 89 to 93, 95, 132-17 and 134 (compared with the current provisions); Addenda. https://www.law.go.kr/법령/특허법 (verified 9 October 2026)